ReviewNature reviews. Urology2017
The evolution of brachytherapy for prostate cancer.
Review in Nature reviews. Urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.
- Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2018Pooled it
- Temporary prostate brachytherapy alone or as boost: Single-institution experience on dose-response assessment focusing on sphincter-related urinary toxicity.Journal of contemporary brachytherapy · 2026Article
- Article
- An Overview of Advanced Materials and Manufacturing Strategies for 3D-Printed Bioengineered Vascular Stents: Toward Next-Generation Drug Delivery Applications.Pharmaceutics · 2026Review
- Radionuclide-labeled oxygen-self-supplying calcium reservoir for high-efficiency radioimmunotherapy via synergistic pyroptosis activation and PD-L1 downregulation.Journal of nanobiotechnology · 2026Article
- Histopathological evaluation of local effects of radioactive iodine seeds in axillary lymph nodes in clinically node-positive breast cancer treated with neoadjuvant systemic therapy.Breast (Edinburgh, Scotland) · 2026Article
- Radioactive seed brachytherapy for malignant tumors with navigation system and 3D-printing template: a propensity score-matched analysis.BMC cancer · 2026Article
- Long-Term Outcomes of Low-Dose-Rate Brachytherapy in Localized Prostate Cancer: A 17-Year Retrospective Analysis of a Single-Center Portuguese Cohort.Journal of clinical medicine · 2026Article
- Sequential microwave ablation combined with radioactive iodine-125 seed implantation successfully cured multiple metastases of gallbladder cancer: A case report.Oncology letters · 2025Article
- Development and characterization of a prototype selenium-75 high dose rate brachytherapy source.Medical physics · 2025Article
- Emerging Technologies in Radiation Therapy: Replacing Traditional Isotope-based Modalities.Health physics · 2025Review
- Mechanisms underlying prostate cancer sensitivity to reactive oxygen species: overcoming radiotherapy resistance and recent clinical advances.Cancer biology & medicine · 2025Review
- Examining the role of elective pelvic radiotherapy in patients Diagnosed with high- and very High-Risk Non-Metastatic prostate cancer.Clinical and translational radiation oncology · 2025Article
- A review of artificial intelligence in brachytherapy.Journal of applied clinical medical physics · 2025Review
- From conventional therapy to novel nano-based approaches. A focus on prostate cancer.Nanomedicine (London, England) · 2025Review
- Long-Term Outcomes After High-Dose-Rate Brachytherapy and Hypofractionated External Beam Radiotherapy in Very High-Risk Prostate Cancer: A 24-Year Follow-Up.Biomedicines · 2025Article
- Resistance to Radiotherapy in Cancer.Diseases (Basel, Switzerland) · 2025Review
- Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting Localized Prostate Cancer Management.Research and reports in urology · 2025Review
- High-dose-rate brachytherapy lowers travel burden for men with localized prostate cancer compared with external beam radiation.Frontiers in urology · 2025Article
- Observational
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
Abstract
Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for select patients with prostate cancer of any risk group. The benefits of HDR-BT over LDR-BT include the ability to use the same source for other cancers, lower operator dependence, and - typically - fewer acute irritative symptoms. By contrast, the benefits of LDR-BT include more favourable scheduling logistics, lower initial capital equipment costs, no need for a shielded room, completion in a single implant, and more robust data from clinical trials. Prospective reports comparing HDR-BT and LDR-BT to each other or to other treatment options (such as external beam radiotherapy (EBRT) or surgery) suggest similar outcomes. The 5-year freedom from biochemical failure rates for patients with low-risk, intermediate-risk, and high-risk disease are >85%, 69-97%, and 63-80%, respectively. Brachytherapy with EBRT (versus brachytherapy alone) is an appropriate approach in select patients with intermediate-risk and high-risk disease. The 10-year rates of overall survival, distant metastasis, and cancer-specific mortality are >85%, <10%, and <5%, respectively. Grade 3-4 toxicities associated with HDR-BT and LDR-BT are rare, at <4% in most series, and quality of life is improved in patients who receive brachytherapy compared with those who undergo surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.